Targeted Osmotic Lysis (TOL)
Advanced/Invasive Cancers
Key Facts
About Oleander Medical Technologies
Oleander Medical Technologies is pioneering a novel, physics-based oncology platform called Targeted Osmotic Lysis (TOL), which exploits the overexpression of sodium channels in advanced cancer cells. The treatment involves administering digoxin to block sodium-potassium pumps, followed by application of a pulsed electric field to open sodium channels, causing cancer cells to swell and burst osmotically. Led by a team with deep scientific and operational expertise, the company is advancing this pre-clinical program with the potential to address invasive, late-stage cancers that are poorly served by current therapies. If successful, TOL could offer a new treatment paradigm with a favorable safety profile due to its selective mechanism.
View full company profile